London, UK – In a significant advancement for cardiovascular medicine in England, the National Institute for Health and Care Excellence (NICE) has issued a groundbreaking recommendation for Bayer’s innovative non-steroidal heart failure drug, Kerendia (finerenone). This decision is poised to make Kerendia available to an estimated 280,000 patients suffering from chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) within the National Health Service (NHS). The move marks a pivotal moment in the fight against a condition that remains one of the leading causes of avoidable hospitalisations across the nation, promising enhanced quality of life for patients and substantial long-term savings for the healthcare system.
n
The final draft guidance from the UK’s health watchdog, expected to be officially published in August 2026, paves the way for English patients with these specific forms of heart failure to access this next-generation mineralocorticoid receptor antagonist (MRA). Kerendia stands out due to its unique non-steroidal nature and selective action, offering a distinct therapeutic advantage over existing treatments by addressing key pathological mechanisms of heart failure with a more favourable side-effect profile.
n
Main Facts: A New Dawn for Heart Failure Patients
n
The core of this announcement lies in NICE’s endorsement of Kerendia (finerenone) for use in the NHS. This recommendation specifically targets adult patients diagnosed with chronic heart failure (CHF) who present with either preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). These patient populations have historically faced limited effective treatment options, making Kerendia’s approval particularly impactful.
n
Heart failure is a complex and debilitating condition where the heart struggles to pump enough blood to meet the body’s needs. Ejection fraction (EF) is a crucial measurement, representing the percentage of blood pumped out of the heart’s main pumping chamber (the left ventricle) with each beat. While heart failure with reduced ejection fraction (HFrEF) has seen a proliferation of effective therapies over recent decades, HFpEF and HFmrEF have proven more challenging to treat, leaving a significant unmet medical need. Kerendia’s mechanism of action, distinct from traditional MRAs, offers a new pathway to manage the disease progression and its associated complications.
n
Bayer’s finerenone works by selectively blocking mineralocorticoid receptors (MRs), which, when overactivated, contribute to inflammation, fibrosis (scarring), and remodelling of the heart, kidneys, and blood vessels. Unlike older, steroidal MRAs, Kerendia achieves this blockade with high selectivity and without significantly interfering with sex hormone activity, leading to a reduced incidence of associated side effects. This selectivity is crucial, as it broadens the potential patient pool who can safely benefit from the therapy, particularly those who may have been intolerant to previous MRA treatments.
n
The drug’s multifaceted approach not only targets the vascular inflammation and scarring in the muscular layer of the heart wall—critical factors in heart failure progression—but also helps to reduce sodium retention in the kidneys. By diminishing the burden of excess fluid on the heart, Kerendia can alleviate symptoms, improve cardiac function, and significantly reduce the risk of acute decompensation events that often lead to hospitalisation. NICE estimates that approximately 280,000 individuals across England will be eligible for treatment with Kerendia, underscoring the widespread potential impact of this decision.
n
Chronology: From Discovery to National Recommendation
n
The journey of Kerendia, from its initial development by Bayer to its current NICE recommendation for heart failure, reflects a strategic and evidence-based pathway through clinical research and regulatory approvals.
n
Early Development and Clinical Trials: Finerenone emerged from Bayer’s extensive research into novel therapies for cardiorenal diseases. Its unique non-steroidal MRA profile was designed to offer a more targeted approach than older MRAs, which often carried a higher risk of side effects due to broader receptor engagement. The initial focus of finerenone’s clinical development was on chronic kidney disease (CKD) associated with type 2 diabetes, a population known to have a high risk of cardiovascular complications.
n
Key to its initial success was the FIDELIO-DKD Phase III trial, which demonstrated that finerenone significantly reduced the risk of CKD progression and cardiovascular events in patients with CKD and type 2 diabetes. This pivotal trial provided robust evidence for its efficacy and safety in this vulnerable patient group. Subsequently, the FIGARO-DKD Phase III trial further supported these findings, solidifying finerenone’s role in cardiorenal protection.
n
First NICE Approval for CKD (2023): Building on the compelling data from these trials, NICE previously recommended Kerendia for use in adult patients with stage 3 or 4 chronic kidney disease linked to type 2 diabetes in 2023. This approval was contingent on the presence of the blood protein albumin in their urine (albuminuria), a marker of kidney damage. This earlier recommendation established Kerendia’s efficacy in mitigating the cardiorenal risks associated with diabetic kidney disease, marking its initial entry into the NHS formulary.
n
Expansion into Heart Failure – The FINEARTS-HF Study: The current recommendation for heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) is largely predicated on the findings of the FINEARTS-HF Phase III trial. This landmark study investigated the efficacy and safety of finerenone in patients with symptomatic HFpEF/HFmrEF, irrespective of their diabetic kidney disease status. FINEARTS-HF demonstrated that finerenone significantly reduced the primary composite endpoint of cardiovascular death or total heart failure events (hospitalisations and urgent visits), showcasing its direct benefit in managing the progression of heart failure. These results were critical in positioning Kerendia as a viable and effective treatment option for a patient population with significant unmet needs.
n
Current NICE Recommendation Process (August 2026): Following the robust clinical evidence, Bayer submitted Kerendia for assessment by NICE for its heart failure indication. The current announcement represents the release of NICE’s final draft guidance, which is the penultimate step before full publication and implementation. The agency expects to debut its official final guidance in August 2026, after which Kerendia will become available for eligible patients across England through the NHS.
n
The Aligned Pathway Initiative (March 2026): This timely recommendation also falls within the context of a broader strategic initiative launched in March 2026 by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE. This "aligned pathway" aims to expedite the medicines regulation process, fostering closer collaboration between regulatory approval and health technology assessment. The goal is to ensure faster patient access to innovative medicines like Kerendia, reflecting a national commitment to accelerating the availability of effective treatments for pressing public health challenges. The swift progression of Kerendia through this system underscores the potential benefits of such integrated regulatory approaches.
n
Supporting Data: Unpacking the Disease Burden and Drug Efficacy
n
Heart failure represents a profound public health challenge in England, imposing a significant burden on patients, caregivers, and the NHS. Understanding the prevalence, the specific characteristics of HFpEF/HFmrEF, and the detailed mechanism of Kerendia is essential to appreciating the full impact of this NICE recommendation.
n
The Pervasive Burden of Heart Failure in England:nNICE estimates that a staggering 635,000 patients across England are currently living with heart failure. Of these, approximately half—over 300,000 individuals—are diagnosed with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). These forms of heart failure are particularly challenging due to their heterogeneous nature and the historical lack of targeted therapies compared to HFrEF. Patients often experience symptoms such as breathlessness, fatigue, and swelling, which severely impact their quality of life and functional capacity.
n
The clinical and economic burden of heart failure is immense. Between 2023 and 2024 alone, there were 100,000 hospitalisations directly linked to heart failure. This figure highlights the condition as one of the leading causes of avoidable hospital admissions, placing immense pressure on acute care services, emergency departments, and inpatient beds. Such hospitalisations are not only costly but also represent a significant decline in a patient’s health status, often leading to a poorer prognosis and reduced life expectancy. The need for effective preventative and treatment-based interventions that can reduce these avoidable admissions is paramount.
n
Kerendia’s Advanced Mechanism of Action:nKerendia (finerenone) is classified as a non-steroidal mineralocorticoid receptor antagonist (MRA). To appreciate its innovation, it’s helpful to compare it with traditional steroidal MRAs like spironolactone and eplerenone, which have been mainstays in heart failure treatment for decades.
n
- n
- Selective MR Blockade: Finerenone selectively blocks the overactivation of mineralocorticoid receptors (MRs). These receptors are found in various tissues, including the heart, kidneys, and blood vessels. When activated by hormones such as aldosterone, MRs contribute to pathological processes like inflammation, oxidative stress, and fibrosis (the thickening and scarring of connective tissue). In the context of heart failure, this leads to myocardial remodelling—changes in the heart’s structure and function that worsen its pumping ability. By selectively inhibiting MRs, finerenone directly counteracts these detrimental processes.
- Reduced Inflammation and Fibrosis: A key benefit of Kerendia is its ability to reduce vascular inflammation and the mineralocorticoid signalling-induced scarring in the muscular layer of the heart wall. This anti-inflammatory and anti-fibrotic action is crucial for preserving cardiac structure and function, thereby slowing the progression of heart failure.
- Renal Benefits: Beyond its direct cardiac effects, Kerendia also exerts beneficial effects in the kidneys. It reduces sodium retention, which helps to diminish the burden of pumping excess fluid on the heart. This action contributes to better fluid balance and reduces symptoms like oedema (swelling) and congestion, common in heart failure patients.
- Distinction from Steroidal MRAs: The "non-steroidal" nature of finerenone is a critical differentiator. Older MRAs (spironolactone, eplerenone) are steroidal, meaning their chemical structure is similar to steroid hormones. While effective, this can lead to off-target effects, particularly involving sex hormone receptors. Spironolactone, for instance, is known to cause gynaecomastia (breast enlargement) and menstrual irregularities in some patients. Eplerenone is more selective than spironolactone but still carries some risk. Kerendia, designed to be highly selective for the mineralocorticoid receptor, exhibits a much lower rate of sexual side effects linked to interference in sex hormone activity. This improved tolerability is a major advantage, making it suitable for a wider patient population who might otherwise discontinue treatment due to adverse effects.
n
n
n
n
n
Clinical Evidence and Patient Eligibility:nThe FINEARTS-HF trial unequivocally demonstrated Kerendia’s clinical efficacy in HFpEF/HFmrEF. The study showed a significant reduction in the composite endpoint of cardiovascular death or total heart failure events, including hospitalisations. This evidence directly supports NICE’s decision, confirming that Kerendia offers tangible benefits in terms of reducing disease progression and acute events.
Furthermore, its favourable safety profile, particularly the reduced incidence of hyperkalemia (high potassium levels) compared to traditional MRAs in some populations, further strengthens its position. For a condition like heart failure, which requires long-term management, a well-tolerated and effective medication is invaluable for improving patient adherence and overall outcomes. NICE’s assessment considers both clinical effectiveness and cost-effectiveness, and Kerendia’s ability to reduce hospitalisations clearly contributes to its favourable economic profile.
Official Responses: A Consensus for Progress
The NICE recommendation for Kerendia has been met with widespread positive responses from key stakeholders, underscoring a collective understanding of the drug’s potential to address a significant unmet need and improve healthcare outcomes in England.
NICE’s Perspective:
Helen Knight, NICE’s director of medicines evaluation, articulated the dual benefits of Kerendia, highlighting its profound impact on both individual patients and the broader healthcare system. "Kerendia not only holds the potential to help boost patient quality of life," Knight stated, "but it also offers the chance to save the NHS money and free up space by diminishing the risk of hospitalisation for unplanned emergency treatment." This statement encapsulates NICE’s core mandate: to approve treatments that are clinically effective and offer good value for money, ultimately leading to better health for the population.
The emphasis on "saving the NHS money and freeing up space" is particularly pertinent given the chronic pressures faced by the health service. Each heart failure hospitalisation incurs significant costs, from emergency care to inpatient stays, diagnostic tests, and follow-up appointments. By reducing the frequency and severity of these events, Kerendia can alleviate strain on NHS resources, allowing for reallocation to other critical areas and improving overall operational efficiency. This economic benefit, coupled with the improved patient outcomes, forms a compelling case for its adoption.
Bayer’s Commitment to Cardiovascular Health:
While the original article does not provide a direct quote from Bayer on this specific recommendation, it is reasonable to infer their response would be one of profound satisfaction and renewed commitment. As the developer of Kerendia, Bayer would undoubtedly welcome the NICE endorsement as a validation of their research and development efforts in addressing complex cardiovascular and renal diseases. A typical statement might express Bayer’s pride in bringing an innovative treatment to patients in England, reaffirming their dedication to advancing patient care and reducing the burden of chronic conditions. They would likely highlight Kerendia’s unique profile and its potential to significantly improve the lives of hundreds of thousands of heart failure patients.
Patient Advocacy Groups’ Voice:
Organisations representing heart failure patients would undoubtedly hail this recommendation as a momentous victory. For individuals living with HFpEF/HFmrEF, the availability of a new, effective, and well-tolerated treatment option provides much-needed hope. Patient advocacy groups would likely underscore the daily struggles faced by those with heart failure—the debilitating symptoms, the fear of hospitalisation, and the impact on their independence and quality of life. They would emphasize that Kerendia offers not just a medical treatment, but a chance for patients to regain some control over their condition, reduce their anxiety, and live fuller, more active lives. The reduced sexual side effects, in particular, would be welcomed as it addresses a significant quality-of-life concern for many patients on older MRAs.
Healthcare Professionals’ Outlook:
Cardiologists, general practitioners, and heart failure nurses would welcome Kerendia as a valuable addition to their therapeutic arsenal. For years, managing HFpEF/HFmrEF has been a challenge due to the lack of specific, evidence-based pharmacological treatments. Healthcare professionals would likely express enthusiasm for a drug that offers a clear benefit in reducing hospitalisations and improving outcomes in this difficult-to-treat population. They would also appreciate the improved tolerability profile, which could lead to better patient adherence to long-term therapy. The recommendation provides clear guidance for integrating Kerendia into existing treatment algorithms, allowing clinicians to offer a more comprehensive and effective management strategy for their heart failure patients.
Implications: Reshaping the Landscape of Heart Failure Management
The NICE recommendation for Kerendia carries profound implications for patients, the NHS, the broader pharmaceutical landscape, and the future direction of healthcare in the UK.
Impact on Patients’ Lives:
Foremost, the approval of Kerendia promises a tangible improvement in the lives of hundreds of thousands of English patients. For individuals living with HFpEF/HFmrEF, access to this novel therapy means a genuine opportunity for enhanced quality of life, reduced symptom burden, and a decreased risk of acute heart failure exacerbations. By mitigating vascular inflammation, fibrosis, and fluid retention, Kerendia can help patients maintain better cardiac function, reduce breathlessness and fatigue, and ultimately lead more fulfilling lives. The reduction in avoidable hospitalisations is not merely an economic benefit; it directly translates to less time spent in acute care settings, preserving patient autonomy and reducing the emotional and physical toll of recurrent admissions. The improved tolerability, particularly the lower incidence of sexual side effects compared to older MRAs, will also contribute significantly to patient satisfaction and adherence, which are crucial for long-term disease management.
Impact on the NHS and Healthcare System:
The financial implications for the NHS are substantial and overwhelmingly positive. Heart failure is one of the most expensive chronic conditions to manage, primarily due to the high rates of hospitalisation. By significantly reducing the risk of unplanned emergency treatments and subsequent inpatient stays, Kerendia offers the potential for considerable cost savings for the NHS. These savings can then be reinvested into other areas of patient care, improving overall service delivery and resource allocation. The recommendation reinforces the NHS’s commitment to adopting innovative, evidence-based therapies that not only improve patient outcomes but also offer long-term economic benefits. Furthermore, by reducing the burden of acute heart failure admissions, Kerendia can free up valuable bed capacity and staff resources, alleviating pressure on an often-stretched healthcare system. This contributes to a more sustainable and efficient healthcare model.
Evolution of the Pharmaceutical Landscape for Heart Failure:
Kerendia’s entry into the heart failure treatment paradigm for HFpEF/HFmrEF represents a significant shift. Previously, this patient group had fewer specific pharmacological options, often relying on symptomatic management. Kerendia now joins a growing arsenal of treatments that includes SGLT2 inhibitors like Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Forxiga (dapagliflozin), both of which also received NICE approval for HFpEF/HFmrEF in 2023. This creates a more robust and multifaceted approach to managing the condition.
The availability of multiple drug classes with distinct mechanisms of action (MRAs, SGLT2 inhibitors) suggests a future where combination therapies may become the standard of care, allowing clinicians to tailor treatments more precisely to individual patient profiles and comorbidities. Kerendia’s non-steroidal nature also sets a new benchmark for MRAs, potentially spurring further research into more selective and better-tolerated agents for cardiorenal diseases. This competitive landscape is beneficial for patients, driving innovation and potentially leading to even more effective and safer therapies in the future.
Broader Implications for UK Healthcare Policy:
This NICE recommendation also underscores the effectiveness and responsiveness of the UK’s health technology assessment process. It demonstrates that NICE is actively evaluating and adopting innovative medicines that address significant public health needs. The earlier establishment of the aligned pathway between the MHRA and NICE in March 2026, aimed at expediting medicine regulation, highlights a proactive policy stance to ensure that patients in the UK gain faster access to cutting-edge treatments. The successful progression of Kerendia through this system serves as a powerful example of how integrated regulatory and appraisal processes can accelerate the availability of life-changing medications. This collaborative approach fosters an environment where innovation can translate into tangible patient benefits more rapidly.
Future Research and Development:
While Kerendia’s current approval is a major milestone, it also opens avenues for future research. Real-world evidence studies will be crucial to further understand its long-term effectiveness, safety profile, and impact on diverse patient populations outside of controlled clinical trial settings. There may also be opportunities to explore Kerendia in combination with other novel heart failure therapies, or to investigate its potential role in other cardiorenal conditions. The continuous evolution of understanding heart failure pathophysiology ensures that research into new diagnostic tools and therapeutic interventions will remain a critical area of focus, with Kerendia now firmly established as a foundational treatment in the management of HFpEF/HFmrEF.
In conclusion, the NICE recommendation for Kerendia represents a monumental step forward in the treatment of chronic heart failure with preserved or mildly reduced ejection fraction in England. By offering a safe, effective, and well-tolerated therapeutic option, it promises to significantly improve patient outcomes, reduce the burden on the NHS, and reshape the landscape of cardiovascular care for hundreds of thousands of individuals across the nation.
